3. Number of treatment‐comparisons by subgroup and three outcomes.

		Outcome
Subgroup	Treatment‐ comparisons N	Overall survival n (% of N)	Progression ‐free survival/time to progression n (% of N)	Objective tumour response rate n (% of N)
Overall:	13	6 (46%)	8 (62%)	10 (77%)
Type of regimen comparison:
Regimen A + platinum agent vs regimen A	2	1 (50%)	1 (50%)	2 (100%)
Regimen A + platinum agent vs regimen B	9	4 (44%)	5 (56%)	7 (78%)
Single agent platinum vs regimen C	2	1 (50%)	2 (100%)	1 (50%)
Type of platinum agent in platinum arm:
Cisplatin in platinum arm	7	2 (29%)	2 (29%)	6 (86%)
Carboplatin in platinum arm	6	4 (67%)	6 (100%)	4 (67%)
First‐line therapy:
First‐line therapy for > 80% of patients	6	5 (83%)	5 (83%)	6 (100%)
Second‐ or third‐line therapy for >=20% of patients	7	1 (14%)	3 (43%)	4 (57%)
Anthracycline in regimens:
No anthracycline in platinum or non‐platinum regimens	13	6 (46%)	8 (62%)	10 (77%)
Taxane in regimens:
No taxane in platinum or non‐platinum regimens	4	1 (25%)	1 (25%)	4 (100%)
Platinum + taxane vs non‐platinum + taxane regimens	2	2 (100%)	2 (100%)	2 (100%)
Platinum + non‐taxane vs non‐platinum + taxane regimens	5	3 (60%)	3 (60%)	4 (80%)
Platinum + taxane vs non‐platinum + non‐taxane regimens	2	(0%)	2 (100%)	(0%)
BRCA1/2 subtype:
Germline BRCA1/2 mutation #	4	1 (25%)	4 (100%)	2 (50%)
Germline BRCA1/2 wild‐type #	2	1 (50%)	2 (100%)	2 (100%)
Homologous recombination deficiency status:
Homologous recombination deficient #	2	1 (50%)	2 (100%)	2 (100%)
Not homologous recombination deficient #	2	1 (50%)	2 (100%)	2 (100%)

^Numbers for each outcome are the number of treatment‐comparison with sufficient data to be included in meta‐analysis for that outcome.

# BRCA1/2 subtype and homologous recombination deficiency status were within‐study subgroupings for Tutt 2018 and Zhang 2018; hence Tutt 2018 and Zhang 2018 both contributed to both BRCA1/2 subroups and both homologous recombination deficiency status subgroups.